Proteotech

ProteoTech, Inc. is at the forefront of introducing small molecule compounds and small peptides as novel therapeutics for the treatment of amyloid diseases.

The goal of anti-amyloid therapies is to disrupt the formation and persistence of fibrillar and toxic substances within the human body that are believed to be crucial in the development and advancement of major human diseases.

The most well known amyloid diseases include Alzheimer’s, Parkinson’s, type 2 diabetes, and Systemic Amyloidosis.

ProteoTech International Alzheimer's Conference Presentation - EXEBRYL-1^®

Download Poster (PDF)

ProteoTech International Alzheimer's Conference Presentation - DP-74

Download Poster (PDF)

News

August 07, 2008
ProteoTech’s Exebryl-1^® Enters Human Clinical Trials for the Treatment of Alzheimer’s Disease

July 29, 2008
Exebryl-1^® Phase I Human Clinical Trial for Alzheimer’s disease commences

July 25, 2008
ProteoTech to present at International Alzheimer’s Conference—Chicago, IL.

May 28, 2008
ProteoTech receives clearance from FDA to proceed with Phase I Human Clinical Trials for Exebryl-1^®

May 15, 2008
ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research

April 28, 2008
ProteoTech files IND for Exebryl-1^® for the treatment of mild-to-moderate Alzheimer’s Disease

scroll